Stay updated with breaking news from Treating Fields. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its phase 2 pilot KEYNOTE-B36 study, conducted in collaboration with MSD, a tradename of Merck Co., Inc., Rahway, NJ, USA.
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric... | June 3, 2022
Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD, a tradename of Merck Co., Inc., Rahway, NJ, USA, to study the use of Tumor Treating Fields
Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET...
Novocure (NASDAQ: NVCR) today announced 19 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2022, to be held in